Stock Events

C4 Therapeutics 

$5.36
55
-$0.12-2.19% Today

Statistics

Day High
-
Day Low
-
52W High
11.88
52W Low
1.06
Volume
1,184,427
Avg. Volume
1,251,380
Mkt Cap
368.8M
P/E Ratio
-2.32
Dividend Yield
-
Dividend
-

Earnings

8MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.76
-0.62
-0.49
-0.35
Expected EPS
-0.35
Actual EPS
-0.41

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CCCC. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap220.15B
Novartis is a global healthcare company that competes in the oncology segment, directly challenging C4 Therapeutics' targeted protein degradation approach.
Roche
RHHBY
Mkt Cap177.61B
Roche operates in various therapeutic areas including oncology, directly competing with C4 Therapeutics in developing cancer treatments.
AMGEN
AMGN
Mkt Cap164.06B
Amgen focuses on human therapeutics, including oncology and inflammation, competing with C4 Therapeutics in the development of novel cancer therapies.
Bristol-Myers Squibb
BMY
Mkt Cap83.6B
Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines, including cancer treatments that compete with C4 Therapeutics' portfolio.
Gilead Sciences
GILD
Mkt Cap81.83B
Gilead Sciences is a biopharmaceutical company that develops and markets therapies in areas including oncology, competing with C4 Therapeutics.
Merck &
MRK
Mkt Cap327.97B
Merck is known for its high-quality research in oncology, directly competing with C4 Therapeutics in the cancer treatment market.
Pfizer
PFE
Mkt Cap163.65B
Pfizer is a global biopharmaceutical company with a broad range of oncology products, competing with C4 Therapeutics in cancer therapy.
Abbvie
ABBV
Mkt Cap277.35B
AbbVie operates in key therapeutic areas including oncology, directly competing with C4 Therapeutics in developing innovative cancer treatments.
Regeneron Pharmaceuticals
REGN
Mkt Cap106.33B
Regeneron Pharmaceuticals focuses on developing and commercializing treatments for cancer among other diseases, competing with C4 Therapeutics.

Analyst Ratings

9$Average Price Target
The highest estimate is $14.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
25%
Hold
75%
Sell
0%

About

Health Technology
Biotechnology
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Show more...
CEO
Employees
145
Country
US
ISIN
US12529R1077

Listings